| Breakdown | TTM | Sep 2025 | Sep 2024 | Sep 2023 | Sep 2022 | Sep 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 46.70B | 49.17B | 42.48B | 31.98B | 23.07B | 15.33B |
| Gross Profit | 16.71B | 14.79B | 17.06B | 13.27B | 9.69B | 6.30B |
| EBITDA | 11.56B | 9.02B | 12.76B | 10.39B | 7.10B | 4.48B |
| Net Income | 6.33B | 3.66B | 7.44B | 6.31B | 4.28B | 2.63B |
Balance Sheet | ||||||
| Total Assets | 82.68B | 83.95B | 71.80B | 55.56B | 41.77B | 31.92B |
| Cash, Cash Equivalents and Short-Term Investments | 11.81B | 10.83B | 8.87B | 12.13B | 11.34B | 11.19B |
| Total Debt | 40.32B | 40.15B | 31.75B | 23.05B | 17.43B | 12.75B |
| Total Liabilities | 47.52B | 47.81B | 38.59B | 29.04B | 21.31B | 15.58B |
| Stockholders Equity | 35.16B | 36.13B | 33.21B | 26.52B | 20.46B | 16.34B |
Cash Flow | ||||||
| Free Cash Flow | 0.00 | -4.38B | -8.52B | -3.06B | -2.73B | -2.79B |
| Operating Cash Flow | 0.00 | 6.03B | 7.48B | 6.80B | 4.42B | 2.58B |
| Investing Cash Flow | 0.00 | -10.43B | -16.83B | -10.31B | -7.75B | -5.78B |
| Financing Cash Flow | 0.00 | 6.37B | 6.08B | 4.30B | 3.49B | 11.05B |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
75 Outperform | ¥30.33B | 17.64 | ― | 2.48% | 3.88% | 0.31% | |
72 Outperform | ¥46.43B | 16.80 | 20.29% | 1.77% | 16.49% | 3.34% | |
72 Outperform | ¥46.37B | 14.37 | ― | 2.63% | 0.30% | -31.28% | |
68 Neutral | ¥96.26B | 20.67 | ― | 2.47% | 1.86% | 1370.48% | |
68 Neutral | ¥28.11B | 15.67 | ― | ― | 31.65% | -51.36% | |
62 Neutral | ¥50.14B | 14.99 | ― | 0.91% | 15.77% | -50.57% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
Amvis Holdings has approved the issuance of paid stock acquisition rights as stock options to its directors and employees, aiming to boost motivation, align interests with shareholders, and support medium- to long-term growth in its comprehensive medical support business. The Sixth Series options will go to CEO Keiichi Shibahara, with exercise tied to performance and share price targets, plus a mandatory exercise clause if the share price falls below 50% of the exercise price to ensure shared downside risk and discourage actions that could depress the stock.
The Seventh Series options will be allotted to directors and employees, including 10,000 rights for Director Kosuke Saita, and are similarly linked to performance and share price goals but without a mandatory exercise condition. If fully exercised, the options would dilute existing shareholders by 2.55% of current shares, which the company views as a reasonable impact given the expected enhancement of corporate and shareholder value through greater equity ownership by management.
The most recent analyst rating on (JP:7071) stock is a Hold with a Yen491.00 price target. To see the full list of analyst forecasts on Amvis Holdings.Inc. stock, see the JP:7071 Stock Forecast page.
Amvis Holdings’ major shareholder, IDEA Capital Co., Ltd., wholly owned by CEO Keiichi Shibahara, has agreed to grant call options over up to 1.1 million Amvis shares to 16 eligible insiders, including directors and employees of the company and its wholly owned subsidiaries. These contracts are strictly between the shareholder and the individuals, and the company itself is not a party to the agreements.
The scheme is designed to better align management and employee interests with those of shareholders and to incentivize contributions to medium- to long-term corporate and shareholder value, mirroring the structure of Amvis’s recently issued paid stock options. Because the options will be satisfied using existing shares held by IDEA Capital rather than newly issued stock, the company emphasized that there will be no share dilution or impact on consolidated financial results.
The most recent analyst rating on (JP:7071) stock is a Hold with a Yen491.00 price target. To see the full list of analyst forecasts on Amvis Holdings.Inc. stock, see the JP:7071 Stock Forecast page.
Amvis Holdings reported consolidated net sales of ¥12.94 billion for the first quarter ended December 31, 2025, up 9.9% year on year, while EBITDA and profit attributable to owners of parent declined 8.6% and 19.7% respectively, reflecting increased costs and margin pressure despite continued top-line growth. The balance sheet remained solid with total assets of ¥83.35 billion and a shareholders’ equity ratio of 44.2%, and the company kept its full-year forecast unchanged, projecting modest 5.1% sales growth but significantly lower profits, along with maintaining its dividend policy of no interim dividend and a year-end payout of ¥4 per share, signaling ongoing shareholder returns amid a profit downcycle.
The most recent analyst rating on (JP:7071) stock is a Hold with a Yen491.00 price target. To see the full list of analyst forecasts on Amvis Holdings.Inc. stock, see the JP:7071 Stock Forecast page.
Amvis Holdings has completed the payment procedures for the disposal of 578,000 shares of its treasury stock as restricted share compensation to 22 employees of the company and its subsidiary, at a disposal price of 468 yen per share for a total of 270.5 million yen. This share-based compensation program is designed to align employee incentives with shareholder interests and strengthen retention by granting restricted shares, reflecting the company’s continued use of equity compensation as part of its human capital and governance strategy.
The most recent analyst rating on (JP:7071) stock is a Hold with a Yen491.00 price target. To see the full list of analyst forecasts on Amvis Holdings.Inc. stock, see the JP:7071 Stock Forecast page.
Amvis Holdings has disclosed that, as of the end of September 2025, it has fallen below the Tokyo Stock Exchange Prime Market’s required tradable share ratio of 35%, reporting a ratio of 34.3% despite meeting all other quantitative listing criteria. The company has entered an improvement period running through September 30, 2026, during which it must restore compliance or risk its shares being placed under supervision and potentially delisted by April 1, 2027. Management attributes the shortfall mainly to low share liquidity caused by a high concentration of holdings among domestic corporate shareholders, management, and treasury stock, and while the CEO acknowledges improving the tradable share ratio as a priority, he prefers to focus on enhancing corporate value rather than selling his own shares into the market. As corrective measures, Amvis will grant 578,000 treasury shares as restricted stock to employees to foster an investor-oriented mindset and modestly raise the tradable share ratio, and it expects further improvement from reduced management shareholdings following organizational and personnel changes, targeting a return to the 35% threshold needed to maintain its Prime Market listing.
The most recent analyst rating on (JP:7071) stock is a Hold with a Yen510.00 price target. To see the full list of analyst forecasts on Amvis Holdings.Inc. stock, see the JP:7071 Stock Forecast page.
Amvis Holdings, Inc. has approved the disposal of 578,000 treasury shares as new restricted shares to 22 employees of the company and its subsidiaries, at a price of 468 yen per share for a total of 270,504,000 yen, with a three-year transfer restriction period ending in February 2029. The restricted stock plan is designed to serve as a medium- to long-term incentive, promoting continuous service, enhancing the group’s corporate value, and reinforcing value sharing with shareholders, with detailed conditions governing transfer restrictions, forfeiture, and treatment in cases of leave, departure, or corporate reorganization, and a pay-in price set in line with the market closing price prior to board approval.
The most recent analyst rating on (JP:7071) stock is a Hold with a Yen510.00 price target. To see the full list of analyst forecasts on Amvis Holdings.Inc. stock, see the JP:7071 Stock Forecast page.
Amvis Holdings, Inc. disclosed that IDEA Capital holds 52.97% of its voting rights, formally identifying it as a controlling shareholder other than a parent company, and clarified that there are currently no significant transactions with this controlling shareholder. The company emphasized a governance policy that, in principle, avoids transactions with controlling shareholders, but where such dealings are necessary, they are subject to Board approval, arm’s-length conditions, and review by a special committee composed of outside directors and outside Audit & Supervisory Board members to protect minority shareholder interests and ensure fairness.
The most recent analyst rating on (JP:7071) stock is a Hold with a Yen510.00 price target. To see the full list of analyst forecasts on Amvis Holdings.Inc. stock, see the JP:7071 Stock Forecast page.